Hypera S.A (HYPE3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hypera S.A (HYPE3) has a cash flow conversion efficiency ratio of 0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$682.57 Million ≈ $133.93 Million USD) by net assets (R$12.26 Billion ≈ $2.40 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hypera S.A - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Hypera S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Hypera S.A carry for a breakdown of total debt and financial obligations.
Hypera S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hypera S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Growthpoint Properties Ltd
JSE:GRT
|
0.036x |
|
Amot Investments Ltd
TA:AMOT
|
0.024x |
|
Indah Kiat Pulp & Paper Tbk
JK:INKP
|
0.018x |
|
Kaori Heat Treatment Co Ltd
TW:8996
|
0.163x |
|
Xiamen Xiangyu Co Ltd
SHG:600057
|
0.259x |
|
Shanghai Mechanical & Electrical Industry Co Ltd A
SHG:600835
|
0.049x |
|
LuxNet
TWO:4979
|
0.097x |
|
Gerdau S.A
SA:GGBR3
|
0.053x |
Annual Cash Flow Conversion Efficiency for Hypera S.A (2006–2024)
The table below shows the annual cash flow conversion efficiency of Hypera S.A from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Hypera S.A.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | R$12.10 Billion ≈ $2.37 Billion |
R$2.54 Billion ≈ $498.32 Million |
0.210x | +0.88% |
| 2023-12-31 | R$11.52 Billion ≈ $2.26 Billion |
R$2.40 Billion ≈ $470.14 Million |
0.208x | +8.72% |
| 2022-12-31 | R$10.66 Billion ≈ $2.09 Billion |
R$2.04 Billion ≈ $400.05 Million |
0.191x | +34.48% |
| 2021-12-31 | R$9.83 Billion ≈ $1.93 Billion |
R$1.40 Billion ≈ $274.53 Million |
0.142x | +11.14% |
| 2020-12-31 | R$9.24 Billion ≈ $1.81 Billion |
R$1.18 Billion ≈ $232.14 Million |
0.128x | +35.35% |
| 2019-12-31 | R$8.71 Billion ≈ $1.71 Billion |
R$823.88 Million ≈ $161.66 Million |
0.095x | -26.67% |
| 2018-12-31 | R$8.27 Billion ≈ $1.62 Billion |
R$1.07 Billion ≈ $209.27 Million |
0.129x | +7.03% |
| 2017-12-31 | R$7.74 Billion ≈ $1.52 Billion |
R$932.61 Million ≈ $183.00 Million |
0.121x | +19.04% |
| 2016-12-31 | R$8.71 Billion ≈ $1.71 Billion |
R$881.76 Million ≈ $173.02 Million |
0.101x | +151.20% |
| 2015-12-31 | R$8.03 Billion ≈ $1.58 Billion |
R$323.69 Million ≈ $63.51 Million |
0.040x | -54.62% |
| 2014-12-31 | R$7.48 Billion ≈ $1.47 Billion |
R$664.00 Million ≈ $130.29 Million |
0.089x | -5.57% |
| 2013-12-31 | R$7.08 Billion ≈ $1.39 Billion |
R$665.78 Million ≈ $130.64 Million |
0.094x | -9.50% |
| 2012-12-31 | R$6.87 Billion ≈ $1.35 Billion |
R$713.80 Million ≈ $140.06 Million |
0.104x | +19.04% |
| 2011-12-31 | R$6.65 Billion ≈ $1.30 Billion |
R$580.23 Million ≈ $113.85 Million |
0.087x | +556.93% |
| 2010-12-31 | R$5.06 Billion ≈ $992.69 Million |
R$67.24 Million ≈ $13.19 Million |
0.013x | -76.53% |
| 2009-12-31 | R$3.42 Billion ≈ $670.62 Million |
R$193.50 Million ≈ $37.97 Million |
0.057x | +25.23% |
| 2008-12-31 | R$1.92 Billion ≈ $376.06 Million |
R$86.64 Million ≈ $17.00 Million |
0.045x | -78.25% |
| 2007-12-31 | R$692.69 Million ≈ $135.92 Million |
R$143.97 Million ≈ $28.25 Million |
0.208x | +148.26% |
| 2006-12-31 | R$37.40 Million ≈ $7.34 Million |
R$-16.11 Million ≈ $-3.16 Million |
-0.431x | -- |
About Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamm… Read more